GLOBAL

RESCON SUMMIT 2026

TIVOLI KOPKE PORTO GAIA HOTEL*****

The Leading Conference
for Respiratory Drug Delivery
& Connected Devices

10 - 11
NOVEMBER
2026

PORTO
PORTUGAL



Inhalation & RESpiratory
Drug Delivery | CONnected Devices

SILVER SPONSORS

Catalent Pharma Services

yirdoc® Next Generation Mesh Nebulizer

ACDIMA BIOCENTER

EVENT PARTNERS

inke

Nebuflow

MEDIA PARTNERS



PHARMA network magazine

OINDP news
Orally inhaled and nasal drug products

Journal of Aerosol Medicine and Pulmonary Drug Delivery
Mary Ann Liebert, Inc. publishers

ON drugDELIVERY

Medhealth Outlook

mediaplanet

BioPharma Asia

RESCON—SUMMIT

The Global RESCON Summit Europe 2026 will take place in Porto, Portugal, on November 10–11, bringing together global leaders in inhalation science, respiratory drug delivery, device innovation, digital health, and regulatory strategy.

The 2026 programme explores the development of next-generation inhaled therapeutics, from small molecules and biologics to RNA-based medicines, alongside advances in dry powder inhalation, nanoparticle engineering, nebulisation, wearable aerosol systems, and emerging respiratory delivery technologies.

A strong focus on dry powder inhaler (DPI) development and commercial manufacturing will examine particulate formulation strategies, product design, aerosol performance, tribo-charging challenges, and the transition from early development to commercial-scale production.

Across two days, scientific and industry leaders will also address predictive lung modelling, translational Lung-on-Chip systems, connected respiratory technologies, digital health, patient-centric aerosol delivery, regulatory requirements for respiratory products, and the growing role of real-world evidence in regulatory decision-making.


Strategic discussions will explore partnerships, investment, and value creation across emerging respiratory platforms, making RESCON Europe 2026 a focused forum for scientific exchange, regulatory insight, and industry collaboration across the global respiratory drug-delivery ecosystem.





EPM Group Executive Summary

WHO You Will Meet




60+
Attendees

20+
Speakers

RATIO


Bio/pharmaceutical manufacturing **65:35** Vendor/Solution Providers

Company Size of Attendees




- 1000+ employees
- 300-999 employees
- 50-299 employees
- less than 49 employees

Job Title of Attendees



- C-level
- SVP/VP
- Snr Director/Director
- Snr Manager/Manager

Attendee Company Annual Turnover



- 1 Billion
- $500-999Million
- $50-499 Million
- <50 Million

HOW You Will Benefit

x1000+

Relive the conference full Acess to documentation, footages and videos.

x10+

Hours of Networking forge new professional contacts.

x15+

Technical Presentations & Case Studies

Companies Attending Our Events



FEEDBACK

94%

RATED EVENT

★★★★★

Quality of the speakers
Sharing of the best practices
Spectrum of industries
Intimate atmosphere

98%

WOULD RECOMMEND THE EVENT TO COLLEAGUES

Learn The Key Practical Points

1. Next-Generation Inhaled Therapeutics
Small molecules, biologics and RNA-based medicines expanding the potential of pulmonary and systemic drug delivery.

2. DPI Formulation & Commercial Manufacturing
Dry powder formulation, particulate engineering, tribo-charging, product design and commercial-scale DPI manufacturing.

3. Advanced Nanoparticle & RNA Delivery
Hybrid lipid–polymer nanoparticles, inhalable nanocarriers and innovative strategies for pulmonary RNA therapeutics.

4. Novel Nebulisation & Aerosol Technologies
Acoustic nebulisation, wearable aerosol systems and emerging technologies for delivering complex inhaled therapeutics.

5. Predictive & Translational Respiratory Models
Lung-on-Chip systems and predictive lung modelling connecting aerosol performance with biological and clinical outcomes.

6. Smart, Connected & Digital Respiratory Care
Connected technologies, digital health and data-driven approaches supporting adherence, monitoring and therapeutic value.

7. Patient-Centric Aerosol Delivery
Pediatric delivery interfaces, device considerations and real-world aerosol performance across diverse patient populations.

8. Regulatory Strategy & Combination Products
Regulatory requirements, drug–device integration and evolving approval challenges for respiratory combination products.

9. Real-World Evidence & Lifecycle Management
Using epidemiological and real-world data to support regulatory decision-making and respiratory product lifecycle strategies.

10. Partnerships, Investment & Commercialisation
Strategic partnerships, platform development, investment readiness, valuation and commercialisation of respiratory innovations.



Meet
The Speakers




Heather Berger

Venture Partner at Forge Life Science Partners



Lukas Peintner

Co-founder and General Manager at Science2Capital



Irena King

Founder & CEO at Surgicure Technologies, Inc.



Ana Grenha

Associate Professor at Drug Delivery Lab, University of Algarve



Amrit Paudel

Scientific Director at Johnson & Johnson



Alfredo García Arieta

Head of Pharmacokinetics and Generic Medicines of the Spanish Agency for Medicines



Francesca Ungaro

Professor at the Department of Pharmacy, University of Naples Federico II



Olivia Merkel

Professor and Chair of Drug Delivery at LMU Munich



Ulf Krueger

Chief Executive Officer at PULMOTREE



Maurits Huigen

CEO at Gilbert



Carsten Ehrhardt

Professor in Biopharmaceutics at Trinity College Dublin



Sabine Häussermann

Founder at Innovation HealthTech



Arunima Sengupta

Scientific Director at Alexis Technologies



Eva Littringer

Advisor to MED-EL



Michal Raciborski

Managing Partner Financial Sponsors at Alira Health



Alan Watts

Director, Innovation & Partnerships, Orally Inhaled Products at Catalent



Puja Myles

Director, Clinical Practice Research Datalink (CPRD) at Medicines and Healthcare products Regulatory Agency (**MHRA**)



Israel Amirav

Associate Professor of Pediatrics at University of Alberta



Elijah Nazarzade

Founder and CSO at Nebu~Flow



Gur Jai Pal Singh

Chief Scientific Advisor at BBSG Pharm Associates

Scientific Agenda

DAY 0 — MONDAY, NOVEMBER 9

18:00 - 19:30	Pre-Conference Cocktail Reception at CUSCO BAR, Hilton Hotel Gaia

DAY 1 — TUESDAY, NOVEMBER 10

8:30 - 9:00	Welcome Coffee & Conference Registration

Morning Chairperson:
Sabine Häussermann, Innovation HealthTech

Session 1: The Next Frontier of Inhaled Therapeutics

9:00 - 9:30	Is Oral Inhalation a Viable Option for Systemic Drug Delivery? **Carsten Ehrhardt, Professor in Biopharmaceutics at Trinity College Dublin**
9:30 - 10:00	Machine-Learning-Supported Development of RNA Nanocarriers for Inhalation **Olivia Merkel, Professor and Chair of Drug Delivery at LMU Munich**
10:00 - 10:30	Speed Networking
10:30 - 11:00	Morning Coffee Break
11:00 - 11:30	Harnessing RNA Therapeutics for Inhalation Through Hybrid Lipid–Polymer Nanoparticles **Francesca Ungaro, Full Professor of Drug Delivery at the Department of Pharmacy, University of Naples Federico II**

Session 2: Engineering the Platform: DPI, Devices & Delivery Performance

11:30 - 12:00	Beyond Conventional Dry Powders: Engineering Particulate Platforms for Pulmonary Drug Delivery **Ana Grenha, Associate Professor at Drug Delivery Lab, University of Algarve**
12:00 - 12:30	Understanding, De-Risking, and Mitigation of Tribo-Charging in DPI Development **Amrit Paudel, Scientific director at Johnson & Johnson**
12:30 - 13:00	Prepared for Launch: Manufacturing a Commercial DPI **Alan Watts, Director, Innovation & Partnerships, Orally Inhaled Products at Catalent**
13:00 - 14:00	Lunch Break

Afternoon Chairperson:
Carsten Ehrhardt, Trinity College Dublin

Session 3: Advanced Inhalation Technologies, Modelling & Translational Development

14:00 - 14:30	Acoustic Nebulisation for Inhalation Delivery of Biologics: Recent Advances and Future Perspectives **Elijah Nazarzadeh, Founder and CSO at Nebu~Flow**
14:30 - 15:00	Multimodal Lung-on-Chip Inhalation Models for Toxicity and Therapeutic Assessment **Arunima Sengupta, Scientific Director at Alexis Technologies**

15:00 - 15:30	Redefining targeted lung delivery: from aerosol engineering to real time predictive lung modelling **Ulf Krueger, Chief Executive Officer at PULMOTREETechnologies**
15:30 - 16:00	Afternoon Coffee Break
16:00 - 17:00	**Panel Discussion:** Regulatory Convergence & Development Challenges in Next-Generation Inhaled Therapeutics • Regulatory Pathways & Combination Products • Novel Inhaled Therapies & Regulatory Challenges • Pulmonary Delivery & Translational Challenges • Aerosol Performance & Device Integration • Real-World Evidence & Lifecycle Management • Bridging Innovation & Regulatory Expectations **Panelists:** • Carsten Ehrhardt - Trinity College Dublin • Puja Myles - MHRA • Amrit Paudel - Johnson & Johnson • Eva Littringer - MED-EL • Alfredo García Arieta - Spanish Agency for Medicines **Moderator:** Elijah Nazarzadeh — Nebu~Flow
17:00	End of Rescon Summit 1st day
19:00 - 20:00	Port Wine Cellar Tour & Tasting at the Historic Kopke Port Wine Cellars
20:00 - 22:00	Conference Dinner at the Tivoli Kopke Hotel

DAY 2 WEDNESDAY, NOVEMBER 11

8:50 - 9:00	Day 2 Registration & Coffee

Morning Chairperson:
Ulf Krueger, PULMOTREE

Session 4: Regulatory Strategy & Real-World Evidence in Respiratory Drug Delivery

9:00 - 9:30	EU Regulatory Requirements for OIP Generics **Alfredo García Arieta, Head of Pharmacokinetics and Generic Medicines of the Spanish Agency for Medicines**
9:30 - 10:00	Regulatory Complexity in Approval of Respiratory Combination Products **Alfredo García Arieta, SAM on behalf of Gur Jai Pal Singh, BBSG**
10:00 - 10:30	Leveraging Real-World Data for Regulatory Decision-Making in Respiratory Products **Puja Myles , Director, Clinical Practice Research Datalink (CPRD) at MHRA**

Session 5: Next-Generation Inhalation Devices & Patient-Centric Delivery

10:30 - 11:00	Morning Coffee Break
11:00 - 11:30	Next-Gen Inhaled Therapies Require Next-Gen Delivery Solutions **Maurits Huigen , Chief Executive Officer at Gilbert**
11:30 - 12:00	From Aerosol Performance to Clinical Reality: Pediatric Delivery Interfaces, Spacers, Masks, and Real-World Drug Delivery in Infants and Young Children **Israel Amirav, Associate Professor of Pediatrics at University of Alberta**

12:00 - 12:30	Beyond the Molecule: HowDigital Health Unlocks the Full Value of Inhaled Therapies **Sabine Häussermann, Founder at Innovation HealthTech**
12:30 - 13:00	Technical Feasibility of Developing a Wearable Aerosol Generating Device **Eva Littringer, Advisor to MED-EL**
13:00 - 14:00	Lunch Break
14:00 - 15:00	**Panel Discussion:** Building Investable Respiratory Platforms: What Drives Partnerships, Valuation & Scale • Platform Defensibility & Strategic Fit • Technical Validation & Clinical Translation • De-Risking Milestones That Move Valuation • From Founder to Funded • Partnerships, Scale-Up & Exit Strategies **Panelists:** • Irena King — Surgicure Technologies • Lukas Peintner — Science2Capital • Michal Raciborski — Alira Health • Heather Berger — Forge Life Science Partners • Ulf Krueger — PULMOTREE **Moderator:** Alan Watts — Catalent
15:00	End of Global RESCON Summit




BioTech Pharma Summit | EPM Group


Speakers Biographies



Olivia Merkel

Professor and Chair of Drug Delivery at LMU Munich

Olivia Merkel has been a Professor of Drug Delivery at LMU Munich since 2015, Chair since 2022, and Co-Director of the Department of Pharmacy since 2024. She is a Registered Pharmacist, received a MS (2006) and a PhD (2009) in Pharmaceutical Technology as well as numerous awards, including an ERC Starting Grant, ERC Proof-of-Concept Grant and ERC Consolidator Grant, the APV Research Award and the Carl-Wilhelm-Scheele-Award. Merkel is the co-spokesperson for the BMBF Future Cluster CNAT-M and an author of over 120 articles and book chapters. She served as NIH reviewer from 2014-2015, SNSF reviewer from 2018-2022, is an Editorial Board member for JCR, EJPB, Molecular Pharmaceutics and other journals, Associate Editor for DDTR and WIREs Nanomedicine and Nanobiotechnology, was the President of the German Controlled Release Society in 2020 and the Chair of the CRS Focus Group on Transdermal and Mucosal Delivery from 2020-2022, and currently is a scientific advisory board member of Coriolis Pharma, AMW, and Corden Pharma as well as a co-founder of RNhale.



Michal Raciborski

Managing Partner Financial Sponsors at Alira Health

Dr. Michal Raciborski is Alira Health's Managing Partner, supporting industry players and private equity clients across the full spectrum of healthcare. With over 15 years of experience in the healthcare and financial industries, Michal's expertise focuses on contract manufacturing and packaging in MedTech and Pharma, in-vitro diagnostics, and fluid management markets. Prior to joining Alira Health, Michal gained experience in M&A and ECM sectors at Citi and Credit Suisse in London.
Michal holds PhD degree in finance with focus on Pharma and Biotech capital markets. He also holds both a Dipl.-Kaufmann and a diplôme des Grandes Ecoles from ESCP Europe, a Magister degree from the University of Economics in Poznan, and an MSc from the CASS Business School in London.



Maurits Huigen

CEO at Gilbert

Maurits Huigen has a background in mathematics, informatics, and business administration and build a 20-year career in the pharmaceutical industry taking up national, pan-European leadership roles in large, midsize, and small pharmaceutical companies. He has run his consultancy firm where he advices, supports and/or invests in, either foreign or local companies in the med-tech and pharmaceutical industry. Currently Maurits is CEO of start-up company Gilbert, with a mission to redefine treatment for patients with lung diseases.



Gur Jai Pal Singh

Chief Scientific Advisor at BBSG Pharm Associates

Dr. Gur Jai Pal Singh is the Chief Scientific Advisor at BBSG Pharm Associates since June 2023. Before that he served as a Senior VP and headed a Pharma Company's Respiratory Centre of Excellence. Under his leadership, several orally inhaled products have been successfully developed for the US, EU, and other geographies. Before coming to leadership roles in the private industry, Dr Singh had a 15-years tenure at the US FDA with designation of Senior Expert for Orally Inhaled and Nasal Drug Products (OINDP). He has participated by invitation in a number of expert panels debating regulatory and product development issues related to respiratory drug products.



Francesca Ungaro

Full Professor of Drug Delivery at the Department of Pharmacy, University of Naples Federico II

Francesca Ungaro, Ph.D., is Full Professor of Drug Delivery at the Department of Pharmacy, University of Naples Federico II, Italy, where she leads a research group focused on the design and development of innovative drug delivery systems. Her main areas of expertise include nanomedicine, pulmonary drug delivery, and RNA-based therapeutics, with particular emphasis on nano- and micro-carriers tailored to overcome biological barriers. A pharmacist by training, she holds a Ph.D. in Pharmaceutical Sciences from the University of Naples Federico II. Since 2007, she has been investigating novel strategies for the local treatment of severe lung diseases, including cystic fibrosis, serving as Principal Investigator or collaborator in several multicentre projects aimed at exploiting innovative therapeutics for pulmonary delivery.



Arunima Sengupta

Scientific Director at Alexis Technologies

Arunima Sengupta is the Scientific Director at Alexis Technologies, leading the development of in vitro inhalation platforms designed to address critical challenges in toxicology, consumer or cosmetic product safety, and environmental research. She holds a Ph.D. in Lung Medical Research from Helmholtz Zentrum in Munich, and a Master's in Cell and Cancer Biology from LMU Munich. Arunima has an extensive background in biomedical engineering, having contributed to research on lung-on-chip systems during her postdoctoral work at the Artificial Organs Center, in Bern, Switzerland. She actively collaborates with organizations like PETA. US and the Korean FDA and Animal Free Research UK to promote ethical, human-relevant research models and the broader adoption of animal alternative in vitro testing platforms.



Alfredo García Arieta

Head of Pharmacokinetics and Generic Medicines of the Spanish Agency for Medicines

Dr. García Arieta is Head of Pharmacokinetics and Generic Medicines of the Spanish Agency for Medicines and Health Care Products and Consultant for WHO Prequalification of Medicines Programme. He was also member of the Methodology Working Party and the Pharmacokinetics Working Party at the European Medicines Agency as well as the drafting groups on the Guideline on Quality and Equivalence of Topical Products and the Guideline on Orally Inhaled Products before joining Simulations Plus, Inc. for 6 months in 2024 to gain experience in PBPK. He holds a Bachelor's degree in Pharmacy (1993), a Master's degree in Pharmaceutics and Industrial Pharmacy (1996) and a PhD in Pharmaceutical Technology (1999), all from Universidad Complutense, Madrid, Spain. Dr. García Arieta also holds a Master's degree in Statistics in Health Sciences (2001) from Universidad Autónoma de Barcelona, Spain.



Puja Myles

Director, Clinical Practice Research Datalink (CPRD) at Medicines and Healthcare products Regulatory Agency (MHRA)

Puja Myles is Director of the Medicines and Healthcare products Regulatory Agency's (MHRA) specialist real world data research service, the Clinical Practice Research Datalink (CPRD). She is a public health specialist and prior to joining CPRD, was a public health academic at the University of Nottingham, UK. As a public health academic her research focused on respiratory epidemiology, particularly respiratory infections and in her current role. She is a fellow of the Faculty of Public Health (UK), a senior fellow of the Higher Education Academy (UK) and has a doctorate in epidemiology. In her current role she has contributed to regulatory guidance on how real world data (RWD) could support regulatory decision-making, post-approval evidence generation, and lifecycle management of medical products.



Israel Amirav

Associate Professor of Pediatrics at University of Alberta

Prof. Israel Amirav, MD, is a pediatric pulmonologist with longstanding clinical and research expertise in pediatric aerosol medicine, inhalation therapy, and respiratory drug delivery in infants and young children. He has held academic appointments in pediatrics and pediatric pulmonology, including at the University of Alberta, and currently works at Dana-Dwek Children's Hospital, Tel Aviv. Prof. Amirav's research has focused extensively on the practical and clinical challenges of aerosol delivery in children, including the use of pressurized metered-dose inhalers, valved holding chambers, spacers, facemasks, nebulizers, and pediatric delivery interfaces. His work has addressed key determinants of effective drug delivery in young children, such as mask seal, interface fit, breathing pattern, caregiver technique, crying, cooperation, and the gap between in vitro aerosol performance and real-world clinical effectiveness. He has co-authored numerous publications in pediatric aerosol therapy and respiratory medicine, including studies and reviews on inhaled drug delivery, facemask design, spacer use, and aerosol treatment in infants and preschool children.



Eva Littringer

Co-founder of Oncofuse & RevIVe Medtech GmbH | Advisor to MED-EL

Eva Littringer is Co-founder and inventor at RevIVe Medtech GmbH and Oncofuse GmbH, and serves as Associate Director of Science & Technology at Novartis, where she operates at the intersection of pharmaceutical innovation, medical device development, and entrepreneurial execution to translate breakthrough ideas into real-world patient impact.Her expertise spans small molecule and biologics development within large global pharmaceutical organizations, combined with hands-on experience in pharmaceutical development and regulated medical device innovation—from concept design through validation, clinical translation, and commercialization. She specializes in designing scalable innovation processes, integrating science, engineering, regulatory strategy, and business to accelerate the delivery of high-impact healthcare solutions.



Carsten Ehrhardt

Professor in Biopharmaceutics at Trinity College Dublin

Carsten is Professor in Pharmaceutics and Biopharmaceutics at the School of Pharmacy and Pharmaceutical Sciences. He was elected Fellow of Trinity College Dublin (2013) and the International Society for Aerosols in Medicine (2025). Carsten's research studies the disposition and transport of drugs following their administration to the lungs using pre-clinical in vitro and ex vivo models. Carsten has edited 1 book and (co-) authored 118 peer-reviewed publications. He serves as Associate Editor of Journal of Aerosol Medicine and Pulmonary Drug Delivery and Section Editor of European Journal of Pharmaceutical Sciences, as well as on the editorial advisory boards of European Journal of Pharmaceutics and Biopharmaceutics, Pharmaceutics and Pharmaceutical Research. Carsten also is a member of the inhalation-based Biopharmaceutics Classification System (iBCS) initiative. In 2013, Carsten started the PDD Workshop series, which since alternates annually between Dublin and Istanbul.



Alan Watts

Director, Innovation & Partnerships, Orally Inhaled Products at Catalent Agency (MHRA)

Alan has focused his career on the development of drugs for respiratory delivery. Prior to his role as Director of Technology & Innovation for Inhalation Products at Catalent, Alan was part of Savara Pharmaceuticals where he worked as Associate Director of Pharmaceutical Development on two Phase 3 pulmonary programs and as CMC due diligence lead. Prior, Alan worked at MicroDose Therapeutx on “active” device delivery of powders for inhalation. Alan has also held the position of Research Assistant Professor at the University of Texas at Austin. Alan has a Ph.D. in Pharmaceutics from the University of Texas at Austin and a B.S. in Biomedical Engineering from Louisiana Tech University. Alan is currently Chair of the Inhalation and Nasal Community within the American Association of Pharmaceutical Scientists (AAPS).



Heather Berger

Venture Partner at Forge Life Science Partners

Heather Berger, Ph.D., is a Venture Partner at Forge Life Science Partners, a boutique life science investment fund, focused on novel therapeutics including respiratory products. She is currently a Board Observer for Kinaset Therapeutics, focused on novel inhaled therapeutics for asthma. Prior to this, she served in a variety of operational roles including Chief Business Officer of Iolyx Therapeutics. Heather was previously principal at SR One and at Sofinnova Investments, concentrating on novel opportunities across therapeutic areas; she is a Board Member of Design Therapeutics. Previously, she was an equity research analyst, a chemist at the Astellas Research Institute, and adjunct faculty at the Feinberg Northwestern School of Medicine.



Sabine Häussermann

Founder at Innovation Healthtech

Sabine Häussermann has dedicated over 30 years to the field of respiratory diseases and drug delivery to the lungs. Building on her experience, Sabine turned her attention to digital solutions aimed at improving treatment for respiratory diseases. Her mission is to bring effective healthcare to patients in a cost-efficient manner she founded VisionHealth in 2017.



Irena King

Founder & CEO at Surgicure Technologies, Inc.

Irena King, PhD, is a medical engineer, neuroscientist, and Founder & CEO of Surgicure Technologies, a MedTech company advancing next-generation airway safety solutions for critical care and military medicine. She trained in the MIT–Harvard Health Sciences and Technology (HST) program, with additional training in healthcare management, and has worked across academic medicine and early-stage biotechnology, including research on HIV biomarker discovery and Alzheimer’s vaccine development. Irena also advises early-stage life science startups on strategy and commercialization.



Amrit Paudel

Scientific director at Johnson & Johnson

Currently scientific director at J&J solid state & particle engineering, Amrit has spent a long standing academic and industrial career focusing research and innovation in a wide diversity of drug formulations including solid oral, inhaled, and long acting products. His focus has been towards mechanistic understanding, characterization, control and prediction relevant design and development attributes including stability, manufacturing and bio performances. He has delivered invited talks at several international conferences, published over 150 research papers and book chapters, and is an inventor of diverse drug formulation, and device patents.



Ana Grenha

Associate Professor at Drug Delivery Lab, University of Algarve

Ana Grenha has received her PhD in Pharmacy-Pharmaceutical Technology from the University of Santiago de Compostela – Spain in 2007. She joined the University of Algarve in Portugal for a Professorship in Pharmaceutical Technology in 2007. Since July 2023 she is Associate Professor in Pharmaceutical Technology. She is the PI of the Drug Delivery Laboratory, part of the Centre for Marine Sciences (CCMAR-UAlg). The research group is also keen on exploring the potential of natural materials, namely polysaccharides. Additionally, there is strong expertise on encapsulation technologies, which have been applied in distinct areas ranging from the pharmaceutical area with drug delivery, to aquaculture with the development of specific feeding strategies, and food science in the context of supplementation. She has been the PI of several funded projects, and has authored ca.



Elijah Nazarzadeh

Founder and CSO at Nebu~Flow

Dr. Elijah Nazarzadeh is the founder and Chief Scientific Officer of Nebu~Flow. He holds a Master of Engineering in Fluid mechanics & Thermodynamics, and a Ph.D. in Fluid Mechanics from King's College London, in the UK (2013). Elijah's research in aerosol science builds upon a strong foundation established during his Master's degree. His subsequent research into acoustic aerosolization directly contributed to the development of the Nebu~Flow platform. He has authored more than 15 peer-reviewed journal and conference publications and is named as an inventor on seven patents related to ultrasound and nebulisation technologies. Elijah is a member of the Royal Academy of Engineering and the Institute of Physics in the UK.



Ulf Krueger

Chief Executive Officer at PULMOTREE

Ulf Krueger´s deep knowledge in respiratory drug delivery combined with his strong management skills and innovative entrepreneurial vision are the foundation of PULMOTREE. His comprehensive experience involves key areas across the non-propellant liquid inhaler lifecycle. In his former position as Director – Fox Nebuliser Programs at Vectura, he was responsible for the entire sector of the proprietary mesh nebulizers business. Previously, he held various positions in the research and development department at PARI. He is a graduate biomedical engineer, an inventor listed on numerous patents, and recognized speaker and conference chairman. As a member of The Aerosol Society, and the European Respiratory Society (ERS), he is particularly also involved as PhD student mentor for the TANDEM program at RWTH Aachen University, and chairman of the networking group New Devices, Emerging Therapies and e-Health at the InternationalSociety for Aerosols in Medicine (ISAM).



Lukas Peintner

Co-founder and General Manager at Science2Capital

Lukas Peintner, PhD is co-founder and general manager at Science2Capital GmbH in Innsbruck, Austria. Beside that he works for MED-EL as Clinical Research Manager. He holds BSc and MSc degrees in Biology from the University of Innsbruck and completed his PhD at the Medical University of Innsbruck and the University of South Australia as part of the Molecular Cell Biology and Oncology graduate programme. His doctoral research focused on the regulation of B- and T-cell lymphoma development. Prior to starting Science2Capital, Lukas worked as Business Development Manager at Minaris Regenerative Medicine, Project Manager within the German Biosecurity Programme, and Research Assistant and Lecturer at the University of Freiburg.



Tivoli Kopke Porto Gaia Hotel*****

Overlooking the iconic Douro River and the historic city of Porto, Tivoli Kopke Porto Gaia Hotel offers a truly exceptional setting for the Global RESCON Summit. Blending contemporary luxury with the heritage of the world's oldest Port wine house, the hotel delivers a unique atmosphere where elegance, innovation, and Portuguese culture meet.

Ideally located in Vila Nova de Gaia, the venue features sophisticated meeting spaces, premium accommodations, stunning panoramic views, and refined gastronomic experiences. With seamless access to Porto's vibrant historic center, Tivoli Kopke Porto Gaia provides the perfect backdrop for high-level networking, scientific exchange, and international collaboration in respiratory drug delivery and connected devices.







R. do Barão de Forrester 69,
4400-034 Vila Nova de Gaia



